These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 21211857)

  • 1. Renal glucose reabsorption inhibitors to treat diabetes.
    Bailey CJ
    Trends Pharmacol Sci; 2011 Feb; 32(2):63-71. PubMed ID: 21211857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
    Raskin P
    Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 inhibitors.
    Dardi I; Kouvatsos T; Jabbour SA
    Biochem Pharmacol; 2016 Feb; 101():27-39. PubMed ID: 26362302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
    Basile JN
    J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
    DeFronzo RA; Davidson JA; Del Prato S
    Diabetes Obes Metab; 2012 Jan; 14(1):5-14. PubMed ID: 21955459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
    Jabbour SA
    Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
    Katz PM; Leiter LA
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.
    Ghosh RK; Ghosh SM; Chawla S; Jasdanwala SA
    J Clin Pharmacol; 2012 Apr; 52(4):457-63. PubMed ID: 21543663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
    Vallon V; Thomson SC
    Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
    Washburn WN
    J Med Chem; 2009 Apr; 52(7):1785-94. PubMed ID: 19243175
    [No Abstract]   [Full Text] [Related]  

  • 12. The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors.
    Cangoz S; Chang YY; Chempakaseril SJ; Guduru RC; Huynh LM; John JS; John ST; Joseph ME; Judge R; Kimmey R; Kudratov K; Lee PJ; Madhani IC; Shim PJ; Singh S; Singh S; Ruchalski C; Raffa RB
    J Clin Pharm Ther; 2013 Oct; 38(5):350-9. PubMed ID: 23909868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.
    Misra M
    J Pharm Pharmacol; 2013 Mar; 65(3):317-27. PubMed ID: 23356840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.
    Washburn WN; Poucher SM
    Expert Opin Investig Drugs; 2013 Apr; 22(4):463-86. PubMed ID: 23452053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition.
    Rajeev SP; Cuthbertson DJ; Wilding JP
    Diabetes Obes Metab; 2016 Feb; 18(2):125-34. PubMed ID: 26403227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus.
    Barnett AH
    Postgrad Med; 2013 Sep; 125(5):92-100. PubMed ID: 24113667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond Glycosuria: Exploring the intrarenal effects of SGLT₋₂ inhibition in diabetes.
    Thomas MC; Jandeleit-Dahm K; Bonnet F
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S17-22. PubMed ID: 25554067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Goodwin NC; Mabon R; Harrison BA; Shadoan MK; Almstead ZY; Xie Y; Healy J; Buhring LM; DaCosta CM; Bardenhagen J; Mseeh F; Liu Q; Nouraldeen A; Wilson AG; Kimball SD; Powell DR; Rawlins DB
    J Med Chem; 2009 Oct; 52(20):6201-4. PubMed ID: 19785435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.
    Boyle LD; Wilding JP
    Expert Opin Emerg Drugs; 2013 Sep; 18(3):375-91. PubMed ID: 23968378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus.
    Guthrie RM
    Postgrad Med; 2013 May; 125(3):21-32. PubMed ID: 23748504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.